title: [Effectiveness of eribulin chemotherapy for squamous cell carcinoma of the breast].
abstract: The patient was a 40-year-old woman who was aware of a tumor in her left breast that was gradually increasing in size. Ultrasonography revealed a hypoechoic mass with a skin cyst, approximately 3 cm in size, in the C area of the left breast. Core needle biopsy indicated estrogen receptor (ER) -negative, progesterone receptor (PR) -negative, and human epidermal growth factor receptor 2 (HER2) -negative squamous cell carcinoma. Overall examination did not indicate distant metastasis. A diagnosis of T4bN2aM0, stage IIIB triple-negative left breast cancer was made. Eribulin was administered at a dose of 1.4 mg/m2. The effect of eribulin was considered to be long-term stable disease( long-term SD). The patient did not experience severe adverse events during treatment. After 24 weeks of eribulin treatment, mastectomy of the left breast with axillary lymph node dissection was performed. At present, 1 year after surgery, the patient is alive with no recurrence. We conclude that eribulin chemotherapy is useful for the treatment of patients with squamous cell carcinoma of the breast.
authors.affiliation: Dept. of Surgical Oncology, Osaka City University Graduate School of Medicine.
authors.forename: Shinichiro
authors.initials: S
authors.lastname: Kashiwagi
authors.forename: Tomohisa
authors.initials: T
authors.lastname: Okuno
authors.forename: Sae
authors.initials: S
authors.lastname: Ishihara
authors.forename: Mariko
authors.initials: M
authors.lastname: Ishii
authors.forename: Yuka
authors.initials: Y
authors.lastname: Asano
authors.forename: Mao
authors.initials: M
authors.lastname: Watanabe
authors.forename: Tamami
authors.initials: T
authors.lastname: Morisaki
authors.forename: Naoki
authors.initials: N
authors.lastname: Aomatsu
authors.forename: Satoru
authors.initials: S
authors.lastname: Noda
authors.forename: Hidemi
authors.initials: H
authors.lastname: Kawajiri
authors.forename: Taeko
authors.initials: T
authors.lastname: Nakano
authors.forename: Noriko
authors.initials: N
authors.lastname: Kawakami
authors.forename: Yasuko
authors.initials: Y
authors.lastname: Mitsukawa
authors.forename: Tsutomu
authors.initials: T
authors.lastname: Takashima
authors.forename: Naoyoshi
authors.initials: N
authors.lastname: Onoda
authors.forename: Tetsuro
authors.initials: T
authors.lastname: Ishikawa
authors.forename: Kosei
authors.initials: K
authors.lastname: Hirakawa
mesh_terms: D000328:Adult; D062005:Biopsy, Large-Core Needle; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000601:surgery; D003131:Combined Modality Therapy; D005663:Furans / Q000627:therapeutic use*; D006801:Humans; D007659:Ketones / Q000627:therapeutic use*; D009367:Neoplasm Staging; D064726:Triple Negative Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D000095662:Polyether Polyketides
chemical_list: D005663:Furans; D007659:Ketones; C490954:eribulin; D000095662:Polyether Polyketides